Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00409578 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,101
- Enrollment target
NCT00409578 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 1,101 participants.
The verdict
NCT00409578, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,101 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular hemodynamics, as reflected by a greater reduction in levels of N-terminal proB-type natriuretic peptide (NT-proBNP) compared to placebo in subjects stabilized following acute coronary syndrome (ACS) who are determined to be at high risk due to an elevated concentration of natriuretic peptides.
Interventions
- DRUG Placebo
- DRUG Aliskiren 300 mg
- DRUG Valsartan 320 mg
- DRUG Aliskiren/valsartan 300/320 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,101 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00409578
The ClinicalTrials.gov registry entry for NCT00409578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00409578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00409578 about?
NCT00409578 is a clinical study titled "Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome". The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular hemodynamics, as reflected by a greater reduction in levels of N-termi...
What is the current status of trial NCT00409578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,101 participants. The study started on 2007-02. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00409578?
The interventions under investigation include: Placebo (DRUG), Aliskiren 300 mg (DRUG), Valsartan 320 mg (DRUG), Aliskiren/valsartan 300/320 mg (DRUG).
Who is sponsoring clinical trial NCT00409578?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.